JP2010516662A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516662A5
JP2010516662A5 JP2009545975A JP2009545975A JP2010516662A5 JP 2010516662 A5 JP2010516662 A5 JP 2010516662A5 JP 2009545975 A JP2009545975 A JP 2009545975A JP 2009545975 A JP2009545975 A JP 2009545975A JP 2010516662 A5 JP2010516662 A5 JP 2010516662A5
Authority
JP
Japan
Prior art keywords
prevention
products
treatment
herpes
bronchoconstriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545975A
Other languages
English (en)
Japanese (ja)
Other versions
JP5264773B2 (ja
JP2010516662A (ja
Filing date
Publication date
Priority claimed from FR0700357A external-priority patent/FR2911604B1/fr
Application filed filed Critical
Publication of JP2010516662A publication Critical patent/JP2010516662A/ja
Publication of JP2010516662A5 publication Critical patent/JP2010516662A5/ja
Application granted granted Critical
Publication of JP5264773B2 publication Critical patent/JP5264773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545975A 2007-01-19 2008-01-17 N−(ヘテロアリール)−1−ヘテロアリール−1h−インドール−2−カルボキサミドの誘導体、これらの調製およびこれらの治療用途 Expired - Fee Related JP5264773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0700357A FR2911604B1 (fr) 2007-01-19 2007-01-19 Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR07/00357 2007-01-19
PCT/FR2008/000055 WO2008107544A1 (fr) 2007-01-19 2008-01-17 Derives de n-(heteroaryl)-1-heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
JP2010516662A JP2010516662A (ja) 2010-05-20
JP2010516662A5 true JP2010516662A5 (enExample) 2013-05-02
JP5264773B2 JP5264773B2 (ja) 2013-08-14

Family

ID=38283097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545975A Expired - Fee Related JP5264773B2 (ja) 2007-01-19 2008-01-17 N−(ヘテロアリール)−1−ヘテロアリール−1h−インドール−2−カルボキサミドの誘導体、これらの調製およびこれらの治療用途

Country Status (11)

Country Link
US (1) US7868024B2 (enExample)
EP (1) EP2125787B1 (enExample)
JP (1) JP5264773B2 (enExample)
AR (1) AR064937A1 (enExample)
CL (1) CL2008000127A1 (enExample)
ES (1) ES2624795T3 (enExample)
FR (1) FR2911604B1 (enExample)
PE (1) PE20081689A1 (enExample)
TW (1) TW200900058A (enExample)
UY (1) UY30874A1 (enExample)
WO (1) WO2008107544A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
EP4561991A1 (en) * 2022-07-25 2025-06-04 Cayman Chemical Company, Inc. Novel heterocycles as spla2-x inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
CA2468544A1 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
AR038420A1 (es) * 2002-02-15 2005-01-12 Glaxo Group Ltd Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.

Similar Documents

Publication Publication Date Title
WO2012103216A3 (en) Apparatus and methods for assisting breathing
CY1110519T1 (el) Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
WO2014151456A3 (en) Treatment of inflammatory diseases
EP2491932A3 (en) Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
WO2010151640A3 (en) Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP4591936A3 (en) Treatment of respiratory diseases
JP2016540749A5 (enExample)
WO2010062995A3 (en) Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2008035315A3 (en) Inhibitors of phosphodiesterase type-iv
WO2019016511A3 (en) NOVEL CRYSTALLINE POLYMORPHIC FORMS OF VILANTEROL TRIFENATATE AND PREPARATION METHODS THEREOF
EP2120935A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2016199170A3 (en) Paliperidone palmitate particles and compositions thereof
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
EP2125728A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2006086609A3 (en) Inhibitors of tryptase
MX2021015553A (es) Inhibidores de arginasa novedosos.
EP3172191A4 (en) A novel compound isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the composition comprising the same for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof
TWI926245B (zh) 吸入性一氧化氮用於治療與肺病相關的肺動脈高壓的用途
WO2014062143A3 (en) Combinations of glycopyrrolate and an anticholinergic agent
WO2008035316A3 (en) Phosphodiesterase inhibitors